Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 22, Issue 3, 2012, Pages 206-214

  Sallee, Floyd R ^a   Kollins, Scott H ^b   Wigal, Timothy L ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANFACINE; PLACEBO;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RELEASE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPOTENSION; IMPULSIVENESS; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRESCHOOL CHILD; QT PROLONGATION; SCHOOL CHILD; SCORING SYSTEM; SEDATION; SIDE EFFECT;

ADOLESCENT; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GUANFACINE; HUMANS; IMPULSIVE BEHAVIOR; LEAST-SQUARES ANALYSIS; MALE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84862486935     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2010.0135     Document Type: Article

References (21)

1. American Psychiatric Association: Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, 4th ed. Text Revision. Washington, DC: American Psychiatric Association, 85-93, 2000.
2. Biederman J, Melmed RD, Patel A, McBurnett R, Konow J, Lyne A, Scherer N, for the SPD503 Study Group: A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 121:e73-e84, 2008.
3. Castells X, Ramos-Quiroga JA, Bosch R, Nogueira M, Casas M: Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev June 15; CD007813, 2011.
4. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York: Guilford Press; 1998.
5. Intuniv [package insert]. Wayne, PA: Shire Pharmaceuticals LLC; 2011.
6. Jain R, Segal S, Kollins SH, Khayrallah M: Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 50:171-179, 2011.
7. Kollins SH, Lopez FA, Vince BD, Turnbow JM, Farrand K, Lyne A, Wigal SB, Roth T: Psychomotor functioning and alertness with guanfacine extended release in subject with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 21:111-120, 2011.
8. Lahey BB: Should the combined and predominantly inattentive types of ADHD be considered distinct and unrelated disorders? Not now, at least. Clin Psychol Sci Pract 8:494-497, 2001.
9. Lahey BB, Pelham WE, Loney J, Lee SS, Willcutt E: Instability of the DSM-IV subtypes of ADHD from preschool through elementary school. Arch Gen Psychiatry 62:896-902, 2005. (Pubitemid 41126884)
10. Lahey BB, Rathouz PJ, Van Hulle C, Urbano RC, Krueger RF, Applegate B, Garriock HA, Chapman DA, Waldman ID: Testing structural models of DSM-IV symptoms of common forms of child and adolescent psychopathology. J Abnorm Child Psychol 36:187-206, 2008.
11. Milich R, Balentine AC, Lynam DR: ADHD combined type and ADHD predominantly inattentive type are distinct and unrelated disorders. Clin Psychol Sci Pract 8:463-488, 2001. (Pubitemid 33681946)
12. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA: The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry 164:942-948, 2007. (Pubitemid 46972911)
13. Riley C, DuPaul GJ, Pipan M, Kern L, Van Brakle J, Blum NJ: Combined type versus ADHD predominantly hyperactive-impulsive type: Is there a difference in functional impairment? J Dev Behav Pediatr 29:270-275, 2008.
14. Sallee F, McGough J, Wigal T, Donahue J, Lyne A, Biederman J, for the SPD503 Study Group: Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48:155-165, 2009.
15. Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AFT, Cohen DJ, Leckman JF: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 158:1067-1074, 2001. (Pubitemid 32623110)
16. Sobanski E, Bruggemann D, Alm B, Kern S, Philipsen A, Schmalzried H, Hesslinger B, Waschkowski H, Rietschel M: Subtype differences in adults with attention-deficit/hyperactivity disorder (ADHD) with regard to ADHD-symptoms, psychiatric comorbidity and psychosocial adjustment. Eur Psychiatry 23:142-149, 2008. (Pubitemid 351273578)
17. Solanto MV, Gilbert SN, Raj A, Zhu J, Pope-Boyd S, Stepak B, Vail L, Newcorn JH: Neurocognitive functioning in AD/HD, predominantly inattentive and combined subtypes. J Abnorm Child Psychol 35:729-744, 2007. (Pubitemid 47353357)
18. Steele M, Jensen PS, Quinn DMP: Remission versus response as the goal of therapy in ADHD: A new standard for the field? Clin Ther 28:1892-1908, 2006. (Pubitemid 46038524)
19. Todd RD, Huang H, Todorov AA, Neuman RJ, Reiersen AM, Henderson CA, Reich WC: Predictors of stability of attention-deficit/hyperactivity disorder subtypes from childhood to young adulthood. J Am Acad Child Adolesc Psychiatry 47:76-85, 2008.
20. Willcutt EG, Chhabildas N, Pennington BF: Validity of the DSM-IV subtypes of ADHD. ADHD Report 9:2-5, 2001.
21. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC: The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:655-679, 2011.